Vanda Pharmaceuticals (VNDA) Announces USPTO Dismissal of '432 Patent Inter Partes Review

August 30, 2016 3:01 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of U.S. Patent No. 9,138,432 ("the '432 patent"). The '432 patent was issued by the USPTO in September 2015 and expires in September 2025.

Vanda had previously announced on August 25, 2016 that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane infringed U.S. Patent Nos. RE39,198 ("the '198 Patent") and 8,586,610 ("the '610 Patent") and accordingly issued an injunction barring Roxane from marketing its product until the expiration of the later expiring '610 patent on November 2, 2027.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment